The event will take place on the Belval Campus, MSA 3.500
DAY 1 – Thursday 11 May
8.45 Welcome – Jens Kreisel and Michael Heneka, Luxembourg
9.00 Plenary Talk 1: Cerebrospinal fluid proteogenomic Session 7 – Disease Modeling analyses: identification of novel proteins and therapeutic targets for AD & PD (Carlos Cruchaga, St. Louis)
Session 1 – Genetics
10.00 Evaluating the contribution of biological age in the risk of progressing to dementia (Alfredo Ramirez, Bonn)
10.30 Coffee Break
11.00 Cortical PU.1 ChIPseq profiles uncover a role for PU.1 in microglial polarization (Philip de Jager, New York)
11.30 Step by step: towards a better understanding of the Genetic architecture of AD (Jean-Charles Lambert, Lille)
12.00 Luxembourg National Research Fund presentation
12.15 Lunch and Poster Session
13.30 Plenary Talk 2: Host microbiome interaction in health and disease (Eran Elinav, Rehovot) – virtual
Session 2 – Microbiome
14.30 The microbiota-gut-brain axis as a modulator of cognitive function in brain disorders (Anthony Hannan, Melbourne)
15.00 Natural microbiota-shaped immune responses (Barbara Rehermann, Washington)
15.30 Coffee Break
16.00 2 Blitz Talks
CD300F immune receptor contributes to healthy aging by regulating inflammaging, metabolism and cognitive decline (Evans Frances, Luxembourg)
Microglia engulf hyperactive synapses via ePtdSer-Trem2 signalling in AD (Rueda-Carrasco Javier, United-Kingdom)
Session 3 – Microglia
16.15 Microglial dysfunction and brain disease: mechanims awaiting exploration in comparment-specific neurovascular interactions (Adam Denez, Budapest)
16.45 Autophagy-phagocytosis crosstalk in microglia(Amanda Sierra, Bilbao)
17.15 Mitochondrial metabolism and microglial activity (Alberto Pascual, Sevilla)
17.45 Microglial gene regulatory networks (Nicole Coufal, San Diego)
18.15 Anti-inflammatory clearance of amyloid beta by a novel chimeric phagocytosis inducer (Hyuk Chan Kim, Daejeon)
DAY 2 – Friday 12 May
8.30 Plenary Talk 3: Humanised systems to elucidate the complex response of human microglia to brain pathology and the impact of genetics (Renzo Mancuso, Belgium)
Session 4 – Cancer
9.30 Brain macrophages in inflammation and cancer (Kiavash Movahedi, Brussels)
10.00 The functional heterogeneity of glioma-associated brain immune cells (Bozena Kaminska, Warsaw)
10.30 Coffee Break
11.00 The early neurodegeneration and immune mechanisms in AD (Stefan Teipel, Rostock)
11.30 Plenary Talk 4: Control of neuron activity by microglia (Anne Schäfer, Cologne) – virtual
12.30 Lunch and Poster Session
13.45 2 Blitz Talks
Tumor-associated microglia/macrophage heterogeneity in glioblastoma patients and patient-derived orthotopic xenografts (Michelucci Alessandro, Luxembourg)
Microglia-mediated chronic neuroinflammation impairs neurogenesis (Mohebiany Alma, Germany)
Session 5 – Emerging Targets
14.00 Cerebrospinal fluid immunity in healthy brain aging and neurodegenerative disease (David Gate, Chicago)
14.30 T lymphocytes in aging and animal models of neurodegeneration (Alon Monsonego, Beer-Sheva)
15.00 2 Blitz Talks
Spatial transcriptomics-correlated electron microscopy (Gokce Ozgun, Germany)
CGAS-STING activation in AD (Martorell Paula, Germany)
15.15 Coffee Break
15.45. Sensing DNA as a danger signal through the cGASSTING pathway (Andrea Ablasser, Lausanne)
16.15 Plenary Talk 5: TREM2 risk polymorphisms in AD (Marco Colonna, St. Louis)
Session 6 – Inflammation
17.15 Galectin-3 in AD: a future target in AD? (Tomas Deierborg, Lund)
17.45 Inflammation and immune dysfunction in Parkinson’s disease: targeting the gut-brain axis to reduce risk and progression (Malú Tansey, Gainesville)
18.15 2 Blitz Talks
Real-time mechanisms of exacerbated synaptic remodeling by microglia in acute models of systemic inflammation and tauopathy (Cangalaya Carla, Germany)
A Cre-deleter specific for embryo-derived brain macrophages reveals distinct features of microglia and border macrophages (Brioschi Simone, United-States)
19.00 Carousel Dinner and Poster Session
DAY 3 – Saturday 13 May
9.00 Plenary Talk 6: Modeling neurological disease for drug research (Richard Ransohoff, Boston) – virtual
Session 7 – Disease Modelling
10.00 Elucidating disease states of glia by CRISPR-based functional genomics (Martin Kampmann, San Francisco)
10.30 Coffee Break
11.00 Brain imaging across scales: studying neuronalmicroglial interactions during CNS development (Francesca Peri, Zurich)
11.30 Models and mechanisms of alpha-syniclein pathology (Donato Di Monte, Bonn)
12.00 2 Blitz Talks
NLRP3 contributes to microglial morphology changes, ASC aggregation and long-term behavioural phenotypes after traumatic brain injury (Castro-Gomez Sergio, Germany)
CxCL16-CXCR6 axis involvement in AD-specific CD8+ T-cells brain recruitment (Zattoni Marco, Germany)
12.15 Lunch
13.30 Plenary Talk 7: Role of APOE and the immune response in tau-mediated neurodegeneration (David Holtzman, St. Louis)
Session 8 – Clinical Aspects of Neuroinflammation
14.30 Surfing on waves: fluid biomarkers for neuroinflammation in AD (Charlotte Teunissen, Amsterdam)
15.00. Effect of Aging and Amyloid on Viral-Vector Induced Tauopathy (Marcia Gordon, East Lansing / Michigan)
15.30 Coffee Break
16.00 2 Blitz Talks
Humanized model to study the therapeutic potential on KV1.3-blockade on microglia-mediated neuroinflammation (Afrang Negin, Belgium)
Elucidating the cell-type specific molecular pathways of the blood-CSF barrier – Choroid Plexus (Jauregui-Lozano Juan, United-States)
16.15 Genetic analysis of the human microglial transcriptome across disease pathologies (Towfique Raj, New York)
16.45 Immune dysregulation and astrogliosis as potential mechanisms of cognitive decline in late life (Brianne Bettcher, Denver)
17.00 Wrap up and closing (Michael Heneka, Luxembourg)